Toy Andrew sold $293K of CLOV
Toy Andrew (Chief Executive Officer) sold 62,711 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.67 ($0.29M total) on 2026-07-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may briefly reassess sentiment around insider behavior, but the 10b5-1 designation generally reduces the likelihood of a fundamental repricing.
Market read
A new, primary-source insider sale is disclosed, but it is pre-arranged under 10b5-1, so expected impact is limited.
What to watch
The filing does not disclose reasons for the sale, and the post-transaction share count remains large, limiting inference from a single sale.
Background
The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. /DE.
Ticker impact
Clover Health CEO Toy Andrew sold 62,711 shares on 2026-07-15 at $4.6700, per a new SEC Form 4 filing.
Likely minimal price impact; any reaction is more sentiment-driven than fundamental.
The filing is primary-source and time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider transaction disclosure.
None.
None.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than a change in outlook.
Key entities
- issuerClover Health Investments, Corp. /DE
Subject of the Form 4 insider transaction disclosure.
- insiderToy Andrew
CEO and officer/director who sold shares.
- trading mechanism10b5-1 plan
Pre-arranged plan that typically limits interpretive value of insider sales.
